Seeking Alpha

cholee65

cholee65
Send Message
View as an RSS Feed
View cholee65's Comments BY TICKER:
Latest  |  Highest rated
  • What If Research In Nokia Existed? [View article]
    Great article.... Could make a lot of sense considering the cell phone market is going to be in high demand for a long-time. I could see Facebook buying RIMM though. There was an article out saying that Facebook could double their profits by acquiring RIMM. That being said I think shareholders would take 1 share of Facebook for 1 share of RIMM. That would put us around $27 a share.
    Jan 2 03:53 AM | Likes Like |Link to Comment
  • RIM's Rise Likely For Takeover Talk And Not BB10 [View article]
    This was the best article written about RIMM in the last three months.
    Dec 20 12:09 AM | Likes Like |Link to Comment
  • Research In Motion Is Up Over 100%: Time To Sell? [View article]
    Book Value is $18 per share. Goldman Sachs target is $16 and I believe BB10 will double their revenue. This stock will be at $50 in 18-mos. Just remember analysts are reactive to numbers not predictive in forecasting a totally new line of phones. Samsung came out of no place two years ago. And, this phone is iphone + galaxy/2. So i expect the company to retain 80% of their qwerty sales and overall double their sales. Company will be making 3-4 billion per year in 2014. Put a p/e of 20 on that, we'd be sitting at a market cap of 70 billion or 10x here at $145 a share.
    Dec 17 07:37 AM | Likes Like |Link to Comment
  • Research In Motion Is Up Over 100%: Time To Sell? [View article]
    Nice article. Stock is still down 90% from it's high. And, the macro trend is smart phones are in huge demand. BB10 will fill the gap and grow the company for RIMM. Stock is going back to $50 a share in 18-mos.
    Dec 17 07:17 AM | 1 Like Like |Link to Comment
  • Equity Offering Results In Price Weakness And A Buying Opportunity In A.P. Pharma [View article]
    Made money in APPA in 2010. Don't know if it's a safe bet anymore since all they are doing is making a long last generic. With the cost cutting by hospitals I doubt they will pay full boat for this drug. That's they haven't been able to find a partner.
    Jul 29 02:51 PM | Likes Like |Link to Comment
  • Small-Cap Adjuvants For Cancer Treatment [View article]
    Nice article. Check out Oncovista or OVIT. CEO's last company Genzyme bought for a billion. This one's has a blockbuster tumor and stocks only 30 cents. I think it could be the next Inhibitex.
    Jul 29 02:51 PM | Likes Like |Link to Comment
  • Gold Juniors Ready To Explode? [View article]
    Check out Sacre-Couer Minerals ticker SCM on the Vancouver. Severstal had a bid to buy them for $1.60 over 12-months ago; they didn't complete the purchase because they couldn't get their subsidiary NordGold public on the London; they cancelled the $66 million dollar purchase a day after they couldnt get Nord public. Now the stock is trading at 13 cents after all the Arbs and Severstal unloaded. I think it can triple from here easily. They have a project that could produce 40,000 oz of gold for only $30 million to put in production; plus they are generating cash flow with their alluvial and drilling operation. Company has $30 million of gold proven in the ground in Guyana; this junior has $6.5 million market cap....
    If you pick up 100,000 shares and it goes back to 50 cents; you'd make $37k.. That's what I am aiming for.
    Apr 6 04:51 AM | Likes Like |Link to Comment
  • Cell Therapeutics Has Huge Potential To Double Or Triple Soon [View article]
    CTIC sold their best asset to Spectrum; I hope for shareholders sake they can get a drug approved. Speaking of innovations take a look at Oncovista; the stock is going parabolic. The CEO's last company Genzyme bought for $1 billion and they have $65 million in milestones giving them an NPV of $20 million. The market cap is only $12.5 million and it's closest compareable GENSPERA in San Antonio is fetching Quadruple it's market cap at $62 million. Put it on your list, could be the next Inhibitex. CEO bought 185k shares in past 18-months which is unheard of. http://bit.ly/xrPxih
    Mar 6 08:25 PM | 1 Like Like |Link to Comment
  • The Case For A Lilly Takeover [View article]
    Great article on Eli Lilly. They should focus on buying up a bunch of small biotechs with innovative pipelines. Check out Oncovista; they sold their diagnostic business for up to $65 million in milestones to ALR. OVIT's market cap is sub $20 million and the CEO co-founded Ilex Oncology; which Genzyme bought for $1 Billion and they have two potential blockbuster cancer drugs that take advantage of biomarkers in clinical trial design to improve their odds. Ticker OVIT
    http://bit.ly/xrPxih
    Mar 6 08:32 AM | Likes Like |Link to Comment
  • The Case For A Lilly Takeover [View article]
    Great article on Eli Lilly. They should focus on buying up a bunch of small biotechs with innovative pipelines. Check it out Oncovista; they sold their diagnostic business for up to $65 million in milestones to ALR. OVIT's market cap is sub $20 million and the CEO co-founded Ilex Oncology; which Genzyme bought for $1 Billion and they have two potential blockbuster cancer drugs that take advantage of biomarkers in clinical trial design to improve their odds. Ticker OVIT
    http://bit.ly/xrPxih
    Mar 6 08:32 AM | Likes Like |Link to Comment
  • Hedge Fund Tracking: Seth Klarman, Mohnish Pabrai And Meryl Witmer [View article]
    Here's a derivative play of Alere's Adnagen AG business. Check it out Oncovista; they sold their diagnostic business for up to $65 million in milestones to ALR. OVIT's market cap is sub $20 million and the CEO co-founded Ilex Oncology; which Genzyme bought for $1 Billion and they have two potential blockbuster cancer drugs that take advantage of biomarkers in clinical trial design to improve their odds. Ticker OVIT
    http://bit.ly/xrPxih
    Mar 6 08:27 AM | Likes Like |Link to Comment
  • 5 Large-Cap Healthcare Stocks Undervalued By EPS Trends [View article]
    Great article, I really like Amgen here. Oncovista is under major accumulation. The CEO's last oncology biotech was bought for $1 billion by Genzyme in 2004. Company could easily fetch a $50 million market cap. They also have $65 million in receivables from Alere on the NYSE; 2 potential blockbuster drugs and their market cap is sub $20 million.
    http://bit.ly/xrPxih
    Mar 6 08:23 AM | Likes Like |Link to Comment
  • Varian Medical Systems: Fighting The Global Cancer Burden [View article]
    Great article on Varian; radiation machines are here to stay in the fight against cancer. Varian is the best manufacture in the world. If you are looking for a therapeutic play; take a look at Oncovista, the CEO's last company Genzyme bought for a Billion Dollars. This one trades at 60 cents, here's a great video:
    http://bit.ly/xrPxih
    Mar 5 09:55 AM | Likes Like |Link to Comment
  • Varian Medical Systems: Fighting The Global Cancer Burden [View article]
    Great article on Varian; radiation machines are here to stay in the fight against cancer. If you are looking for a therapeutic play; take a look at Oncovista, the CEO's last company Genzyme bought for a Billion Dollars. This one trades at 60 cents, here's a great video:
    http://bit.ly/xrPxih
    Mar 5 09:53 AM | Likes Like |Link to Comment
  • Analyzing Friday's Noteworthy Insider Buys And Sells In The Healthcare Sector [View article]
    CYTR looks like it could run to $1.00. You know the management team is going to pull out all of the tricks to keep in on the Nasdaq.
    Watch this video on Oncovista; CEO’s last start-up Ilex Oncology, Genzyme bought for a billion dollars. Ilex got two cancer drugs approved faster than any biotech in 2 and 4 years via accelerated approval with FDA. I think OVIT could be a $100+ market cap company valued at $3-4 dollars in 18 months.. http://bit.ly/xrPxih
    Mar 1 11:19 PM | Likes Like |Link to Comment
COMMENTS STATS
38 Comments
16 Likes